[HTBX] Heat Biologics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 0.88 Change: -0.04 (-4.13%)
Ext. hours: Change: 0 (0%)

chart HTBX

Refresh chart

Strongest Trends Summary For HTBX

HTBX is in the medium-term down -28% below S&P in 1 year. In the long-term down -76% below S&P in 2 years and down -92% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Heat Biologics, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer-associated antigens together with a potent immune adjuvant. The company?s products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase I/II clinical trials for the bladder cancer treatment. It is also developing a cell line for the treatment of ovarian and triple negative breast cancer; and HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-58.55% ROE-68.91% ROI
Current Ratio9.85 Quick Ratio Long Term Debt/Equity Debt Ratio0.12
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities11.13 M Cash From Investing Activities-110 K Cash From Operating Activities-4.46 M Gross Profit
Net Profit-3.91 M Operating Profit-3.98 M Total Assets22.83 M Total Current Assets22.15 M
Total Current Liabilities2.25 M Total Debt2.73 M Total Liabilities3.43 M Total Revenue
Technical Data
High 52 week4.29 Low 52 week0.98 Last close1.35 Last change-2.17%
RSI75.28 Average true range0.1 Beta1.26 Volume871.26 K
Simple moving average 20 days17.89% Simple moving average 50 days-0.13% Simple moving average 200 days-23.59%
Performance Data
Performance Week9.76% Performance Month4.65% Performance Quart-17.68% Performance Half-41.3%
Performance Year-68.49% Performance Year-to-date37.76% Volatility daily5.92% Volatility weekly13.23%
Volatility monthly27.12% Volatility yearly93.93% Relative Volume229.83% Average Volume382.16 K
New High New Low


2019-03-11 10:40:00 | HTBX: HS-110 Interim Update

2019-03-05 09:25:00 | Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai

2019-02-28 17:00:00 | Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium

2019-02-26 09:45:00 | These Four Healthcare Stocks Are Heating Up On Tuesday

2019-02-13 10:03:27 | What Type Of Shareholder Owns Heat Biologics, Inc.’s NASDAQ:HTBX?

2019-01-14 14:15:00 | UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDAR in Non-Small Cell Lung Cancer Trial

2019-01-14 08:00:00 | Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDAR in Non-Small Cell Lung Cancer Trial

2019-01-10 08:27:52 | The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

2019-01-10 06:30:00 | Heat Biologics Provides Clinical and Business Update

2019-01-08 06:30:00 | Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

2019-01-04 07:00:00 | Heat Biologics to Present at Biotech Showcase 2019 in California

2018-12-03 10:15:00 | HTBX: Plenty of Catalysts in 2019

2018-11-27 08:38:42 | Durham company rakes in another $13.8M through public offering

2018-11-26 16:00:00 | Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering

2018-11-26 06:00:00 | Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum

2018-11-23 08:15:00 | Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics — What Drives Growth in Today's Competitive Landscape

2018-11-21 15:21:00 | Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

2018-11-21 13:37:33 | Should You Be Concerned About Heat Biologics Inc’s NASDAQ:HTBX Historical Volatility?

2018-11-21 08:04:35 | The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

2018-11-21 07:30:00 | Heat Biologics, Inc. Prices $12,000,000 Public Offering

2018-11-20 15:10:00 | Heat Biologics, Inc. Announces Proposed Public Offering

2018-11-15 07:00:00 | Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update

2018-10-22 07:00:00 | Heat Biologics to Present at Precision: Lung Cancer World R&D Summit

2018-10-19 07:00:00 | Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City

2018-10-10 07:00:00 | Heat Biologics to Present at the 2018 BIO Investor Forum

2018-10-04 07:00:00 | Heat Biologics’ Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator

2018-09-26 15:16:17 | What does Heat Biologics Inc’s NASDAQ:HTBX Balance Sheet Tell Us About Its Future?

2018-08-29 09:45:00 | HTBX: Multiple Milestones on the Horizon

2018-08-29 07:00:00 | Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City

2018-08-15 16:21:04 | Heat Biologics Stock Is a Worthwhile, Speculative Bet

2018-08-14 07:30:00 | Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update

2018-07-30 07:00:00 | Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks

2018-07-16 09:45:00 | HTBX: Heat Biologics: Making an ImPACT on Cancer

2018-06-29 07:10:00 | Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

2018-06-06 13:22:21 | Is Heat Biologics Inc NASDAQ:HTBX Excessively Paying Its CEO?

2018-05-30 07:00:00 | Heat Biologics to Present at the 2018 BIO International Convention

2018-05-25 07:15:00 | Wired News - Clementia Announced Encouraging Phase-2 Part B Data Evaluating Palovarotene for FOP Treatment

2018-05-24 07:15:00 | Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

2018-05-16 08:10:00 | Today’s Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals

2018-05-15 07:00:00 | Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update

2018-05-09 06:51:25 | Heat Biologics Inc NASDAQ:HTBX: Risks You Need To Consider Before Buying

2018-05-08 08:40:58 | This Durham company is $20M richer

2018-05-07 17:10:00 | Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering

2018-05-03 08:30:00 | Heat Biologics, Inc. Prices $18,000,000 Public Offering

2018-05-01 08:24:16 | Benzinga Pro's 5 Stocks To Watch Today

2018-05-01 08:10:00 | Today’s Research Reports on Stocks to Watch: Heat Biologics and Immunomedics

2018-04-23 14:57:47 | Heat Bio looks to milestones, $15.5M from offering

2018-04-18 07:00:00 | Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110

2018-04-10 10:39:23 | Who Are Heat Biologics Inc’s NASDAQ:HTBX Major Shareholders?

2018-03-26 07:00:00 | Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform